Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Regeneus Ltd

Healthcare AU RGS

0.009AUD
-(-%)

Last update at 2024-04-29T00:00:00Z

Day Range

0.0090.009
LowHigh

52 Week Range

0.0030.02
LowHigh

Fundamentals

  • Previous Close 0.009
  • Market Cap3.68M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.72459M
  • Revenue TTM0.99M
  • Revenue Per Share TTM0.003
  • Gross Profit TTM 1.02M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -1.68688M -4.30973M 2.15M -1.06905M -6.02460M
Minority interest - - - - -
Net income -1.68688M -4.38239M 2.15M -3.83633M -5.75382M
Selling general administrative 1.77M 2.78M 4.23M 3.70M 4.44M
Selling and marketing expenses - - - - -
Gross profit - - 7.96M 1.66M 0.03M
Reconciled depreciation - 0.02M 0.05M 0.07M 0.27M
Ebit -1.20446M -4.24480M 2.17M -0.77995M -5.89258M
Ebitda -3.08668M -4.21984M 2.23M -0.70599M -5.62180M
Depreciation and amortization - 0.02M 0.05M 0.07M 0.27M
Non operating income net other - - - - -
Operating income -1.34980M -4.24480M 2.17M -0.77995M -5.89258M
Other operating expenses 0.03M 4.65M 5.53M 5.01M 6.87M
Interest expense 0.29M 0.07M 0.08M 0.27M 0.40M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.26M 0.00000M 0.28M 0.34M 0.52M
Net interest income -0.29020M -0.07265M -0.07504M -0.27069M -0.38372M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.07M -0.18091M 2.77M -0.27078M
Total revenue 0.00000M 0.00000M 7.96M 1.66M 0.03M
Total operating expenses - 4.65M 5.53M 5.01M 6.87M
Cost of revenue - - - - -
Total other income expense net -0.76830M -0.06493M -0.02092M -0.28909M -0.13202M
Discontinued operations - - - - -
Net income from continuing ops -3.37688M -4.30973M 2.15M -1.06905M -6.02460M
Net income applicable to common shares -1.68688M -4.30973M 2.76M -1.06905M -6.02460M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 0.71M 2.55M 5.26M 3.56M 2.54M
Intangible assets - - 0.00000M 0.00000M 0.00000M
Earning assets - - - - -
Other current assets 0.03M 0.03M 0.11M 0.02M 2.12M
Total liab 2.53M 1.48M 2.85M 3.70M 8.93M
Total stockholder equity -1.81496M 1.07M 2.41M -0.13096M -6.38650M
Deferred long term liab - - - - -
Other current liab 0.08M 0.31M 0.18M 1.44M 7.34M
Common stock 38.62M 38.62M 38.29M 38.16M 31.08M
Capital stock 38.62M 38.62M 38.29M 38.16M 31.08M
Retained earnings -42.27701M -38.95131M -36.47984M -38.71818M -37.87538M
Other liab - 0.00092M 3.06M 0.05M 0.18M
Good will - - - - -
Other assets - 1.75M - - 0.00000M
Cash 0.30M 0.10M 3.79M 0.98M 0.26M
Cash and equivalents - - - - -
Total current liabilities 2.53M 1.48M 1.30M 3.63M 8.75M
Current deferred revenue - - - 0.53M -3.42732M
Net debt 1.64M 0.91M -2.25065M 0.14M 3.52M
Short term debt 1.95M 1.01M 0.00530M 1.11M 3.78M
Short long term debt 1.95M 1.00M - 1.10M 3.78M
Short long term debt total 1.95M 1.01M 1.54M 1.12M 3.78M
Other stockholder equity 1.84M 1.41M 0.54M 2.23M 0.41M
Property plant equipment 0.00071M 0.02M 0.03M 0.08M 0.15M
Total current assets 0.71M 0.79M 5.23M 3.48M 2.38M
Long term investments - 1.75M - - 0.00367M
Net tangible assets -0.12496M 1.07M 4.15M -0.13096M -6.38650M
Short term investments 0.00000M 0.07M 0.57M 0.57M 0.60M
Net receivables 0.38M 0.56M 0.75M 1.90M 0.65M
Long term debt - - 1.53M - -
Inventory 0.00000M 0.04M - 0.01M 0.00861M
Accounts payable 0.50M 0.16M 1.11M 0.56M 1.06M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.84M 1.41M 0.60M 0.43M 0.41M
Additional paid in capital - - - - -
Common stock total equity - - - 38.16M 31.08M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 0.16M
Deferred long term asset charges - - - - -
Non current assets total 0.00071M 1.77M 0.03M 0.08M 0.16M
Capital lease obligations - 0.00837M 0.01M 0.02M -
Long term debt total 0.00000M 0.00251M 0.00855M 0.01M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.04894M -0.00847M -0.00778M -0.02549M -0.02549M
Change to liabilities -0.00837M -0.70527M -1.35655M 0.73M 1.28M
Total cashflows from investing activities -0.04894M -0.00847M -0.00778M 0.02M -0.00762M
Net borrowings 0.95M 1.19M -1.10000M -1.25407M 2.78M
Total cash from financing activities 0.92M -0.09784M 0.40M 2.63M 2.78M
Change to operating activities 0.27M 0.22M -0.31456M 1.31M 0.24M
Net income -3.37688M -4.38239M 2.15M -1.08667M -5.75382M
Change in cash 0.21M -3.69757M 2.81M 0.73M -0.83612M
Begin period cash flow 0.10M 3.79M 0.98M 0.26M 1.09M
End period cash flow 0.30M 0.10M 3.79M 0.98M 0.26M
Total cash from operating activities -0.65966M -4.35743M 2.42M -1.91759M -3.60850M
Issuance of capital stock - - 1.50M 3.88M -
Depreciation 0.00642M 0.02M 0.05M 0.07M 0.27M
Other cashflows from investing activities -0.04894M - 0.00000M 0.02M -
Dividends paid - - - - -
Change to inventory - - - 0.00861M 0.00672M
Change to account receivables 0.11M -0.10230M 1.47M -1.46640M -1.46640M
Sale purchase of stock -0.03075M - 0.00000M 3.88M -
Other cashflows from financing activities 0.95M 1.16M -0.00778M 0.05M 4.66M
Change to netincome 0.64M 1.29M -0.18983M -1.51103M 0.62M
Capital expenditures 0.00000M 0.00847M 0.00778M 0.00778M 0.00762M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.08M 0.83M 0.57M 1.54M 2.38M
Stock based compensation - - - - -
Other non cash items - 4.36M -2.15301M 1.00M 5.75M
Free cash flow -0.65966M -4.36589M -0.00778M -1.91759M -0.00762M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RGS
Regeneus Ltd		 - -% 0.009 - - 3.72 3.14 6.79 132.14
CSL
CSL Ltd		 1.50 0.63% 240.21 28.64 32.15 7.65 4.04 5.81 18.03
TLX
Telix Pharmaceuticals Ltd		 -0.08 0.32% 24.92 166.67 57.47 10.68 14.73 10.52 89.03
MSB
Mesoblast Ltd		 -0.03 1.80% 1.64 - 454.55 367.78 2.98 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 0.10 0.80% 12.54 11.61 75.76 7.37 4.49 6.61 8.03

Reports Covered

Stock Research & News

View All

Profile

Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company's platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing. The company was incorporated in 2007 and is headquartered in Paddington, Australia.

Regeneus Ltd

16 Goodhope Street, Paddington, NSW, Australia, 2021

Key Executives

Name Title Year Born
Mr. Karolis Rosickas Chief Exec. Officer NA
Prof. Graham Vesey Ph.D. Chief Scientific Officer & Exec. Director 1965
Dr. Charlotte Morgan Ph.D. Head of R&D NA
Ling Leung Hang Company Sec. NA
Mr. Karolis Rosickas Chief Executive Officer NA
Prof. Graham Vesey Ph.D. Chief Scientific Officer & Executive Director 1965
Dr. Charlotte Morgan Ph.D. Head of Research & Development NA
Ling Leung Hang Company Secretary NA
Mr. Karolis Rosickas Chief Executive Officer NA
Prof. Graham Vesey Ph.D. Chief Scientific Officer & Executive Director 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.